Chapter 23: Local Anesthetics

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

You know, when you think about like major medical procedures, there's always that really dramatic cinematic moment where the anesthesiologist leans over, tells the patient to count back backward from 10.

Right, the classic movie trope.

Yeah, exactly.

And before they even hit seven, their entire system just completely shuts down.

I mean, it is highly effective, but it's also this massive systemic event.

It really is.

It's the equivalent of pulling the main breaker on a house.

General anesthesia suppresses the entire central nervous system.

Wow.

And, you know, it is absolutely necessary for major surgeries, but it comes with a pretty

I mean, your body's basically temporarily forgetting how to breathe on its own.

Which is terrifying if you think about it too much.

But what if you don't need to do a heart transplant?

What if you are an advanced practice nursing or physician assistant student?

And welcome, by the way, if you are sitting there listening to this deep dive right now.

What if your patient just needs a nasty laceration sutured in the ER?

Right.

Or they're having some minor dermatological procedure.

Yeah.

You really don't want to shut down the whole power grid of the body if you only need to, you know, change a single light bulb in the kitchen.

That targeted strike.

That's actually the entire mission for today's deep dive.

We're sitting down with you for a one -on -one clinical tutoring session to just really master local anesthetics.

OK, so where do we start?

Well, the central pharmacotherapeutic focus here is brilliant in its simplicity, really.

We want to suppress pain by blocking impulse conduction along nerve axons in one specific highly localized area.

So you get this incredible clinical advantage of eliminating pain, but without causing that generalized depression of the entire central nervous system.

Exactly.

It is a massive reduction in patient risk.

But to actually use these drugs safely at the bedside, we really need to understand

and down at the microscopic level, how they actually stop a pain signal from reaching the brain.

Right.

So let's talk about the chemicals.

Clinically, we categorize these local anesthetics into two major chemical families.

You have the esters and the amides.

Esters and amides.

OK.

Right.

And our prototype for the ester family is chloroprocane, and our prototype for the amide family is lidocaine.

Got it.

And the distinction between them, it basically boils down to the specific chemical bond linking their molecular structure together.

So either an ester bond or an amide bond.

I'm guessing that chemical bond isn't just like trivia for a pharmacology exam.

Does the body actually handle those two structures differently?

Completely differently.

That structural difference dictates how the drug is metabolized, which in turn drives the risk of allergic reactions.

Oh, interesting.

How so?

Well, the ester type anesthetics are metabolized right there in the bloodstream by enzymes called plasma esteroses.

The amy type agents, on the other hand, they have to be transported to the liver and are metabolized by hepatic enzymes.

So if I'm treating a patient with, say, compromised liver function, that chemical difference suddenly becomes incredibly important when I'm choosing an anesthetic.

Absolutely.

And what about the allergy risk you mentioned?

Right.

So esters carry a much higher risk of triggering an allergic reaction.

When those plasma esterases break down the ester bond in the blood, one of the resulting

byproducts is a compound that is highly allergenic to a subset of the population.

Ah.

I see it.

But amides don't produce that byproduct, so they carry a very low allergy risk.

OK, so we have our two families, esters and amides.

But once you inject them into the tissue, how are they actually stopping the pain, like mechanically?

So regardless of the family, the mechanism of action is identical.

Local anesthetics stop axonal conduction by physically blocking sodium channels in the nerve membrane.

OK, sodium channels.

Yeah.

For a pain signal and action potential to travel down a nerve toward the brain, sodium ions literally must rush from the outside of the nerve cell to the inside through these specialized microscopic pores.

So if we use an analogy here, think of the axonal sodium channels as the on -ramp for the body's pain highway.

I like that.

If you park a local anesthetic molecule right in the middle of that on -ramp, you block the sodium from entering.

Without that sodium influx, the pain signal simply cannot get into the traffic flow to reach the brain.

Exactly.

A blocked on -ramp means no action potential, which means no perception of pain.

But you have to be incredibly careful as a provider because these drugs are entirely non -selective.

Wait, non -selective?

What does that mean in this context?

They don't have a homing beacon for pain nerves.

They will block the sodium channels of any and all neurons they physically come into contact with.

Wait, if they're totally non -selective to the nerves they touch, why doesn't the patient immediately lose deep pressure sensation and total motor function the exact second the drug touches the tissue?

Why does their face just feel a little numb at first?

That is a great question.

That comes down to the physical architecture of the nerves themselves.

Think of the nervous system like a bundle of different cables.

You have tiny, uninsulated wires, and you have thick, heavily insulated cables.

Okay, that makes sense.

The drug affects all of them.

But the blockade develops at different rates.

Small, non -myelinated neurons, those thin, uninsulated wires, are blocked much more rapidly than the large myelinated nerves.

Ah, because it simply takes more time for the drug molecules to physically diffuse through the thicker tissue and heavy insulation of the larger nerves.

Exactly the case.

And because of this differential sensitivity,

clinical sensations are lost in a very predictable order.

Oh, there's an order to it.

Yeah.

The perception of pain is lost first because those travel on the smallest fibers.

Then the patient loses the sensation of cold, then warmth, then touch, and finally deep pressure.

And if your concentration is high enough and the drug just sits there long enough, motor neurons will eventually be blocked too.

Wow, okay.

So the selectivity we achieve isn't from the drug being, like, smart.

The selectivity comes purely from us, the providers, limiting the geographical area and the time it takes to soak into different tissues.

Precisely.

You control the environment.

Which naturally leads us to the timeline of anesthesia.

I mean, as a clinician, I need to know how fast this drug is going to kick in and how long I have to stitch up my patient before they start feeling the needle.

What dictates that clock?

So the onset of anesthesia, how fast it starts working, is determined by three molecular properties of the drug itself.

Its molecular size, its lipid solubility, and its degree of ionization of the tissue's Let's unpack that last part, ionization.

Sure.

So cell membranes are made of lipids, which are basically fats.

And as we know, water and fat don't mix.

If a drug molecule carries an electrical charge, meaning it's highly ionized, it is water soluble and it'll just bounce right off that fat -based nerve membrane.

But if the molecule is unionized, its lipid soluble can melt right through that fat barrier.

So for the fastest onset, you really want an anesthetic molecule that is small,

highly lipid soluble, and has low ionization, so it can slip right across that lipid bilayer and block the sodium on -ramp immediately.

You've got it.

Now, on the flip side, the termination of the anesthesia happens as those drug molecules naturally diffuse out of the nerve and are carried away by the local bloodstream.

Regional blood flow is the massive determinant of duration here.

That makes sense.

Yeah.

If you inject an anesthetic into an area with a huge blood supply, the drug gets swept away quickly and the numbness wears off fast.

Which brings up a really crucial patient education point.

Pain is a vital physiological warning sign.

It's the body's alarm system telling us tissue is being damaged.

If we artificially disconnect that alarm system, patients can easily suffer severe self -inflicted injuries.

That is so important.

You cannot let a patient leave your clinic without explicit warnings.

You must caution them against activities that could cause unintentional harm until the anesthetic completely wears off.

Right, like the classic example of a dental patient.

Exactly.

Chewing their own lip to the point of severe laceration or someone exposing a numb limb to extreme heat and suffering third degree burns without feeling a single thing.

Now, to manage that local blood flow issue we just talked about, to keep the drug from washing away too quickly, clinicians use a really clever trick, right?

They combine the local anesthetic with a vasoconstrictor, almost always epinephrine.

Right.

Epinephrine literally constricts the local blood vessels, decreasing regional blood flow.

This naturally delays the systemic absorption of the anesthetic into the broader circulatory system.

You know, I always picture epinephrine as a bouncer at a club door.

It stands right there at the local blood vessels, crosses its arms, and basically keeps the anesthetic molecules at the tissue party for a much longer time, stopping them from escaping down the street into the systemic bloodstream.

That bouncer provides two tremendous clinical benefits.

First, it prolongs the local anesthesia significantly, meaning you can often use a lower overall dose of the anesthetic.

And the second benefit.

Second, it reduces the risk of systemic toxicity.

You're establishing a much safer balance between the rate the drug slowly leaks into the circulation and the rate the body can metabolize it.

But there has to be a trade -off.

What happens if the bouncer gets absorbed?

Like what if that epinephrine escapes into the bloodstream?

Then you can see systemic toxicity from the vasoconstrictor itself.

I mean, epinephrine is pure adrenaline.

If it hits the systemic circulation,

it stimulates the adrenergic receptors in the heart and blood vessels, causing tachycardia palpitations, intense nervousness, and hypertension.

Wow.

So, if a patient starts experiencing those extreme cardiac symptoms from the epinephrine absorption,

how do we pump the brakes on that?

If the adrenergic stimulation gets excessive, you can manage those symptoms by administering alpha and beta adrenergic antagonists.

Beta blockers.

Exactly.

These drugs bind to those same receptors and shield them from the adrenaline,

effectively slowing the heart rate back down and relaxing the blood vessels.

That bouncer analogy is so vital because if the anesthetic drug itself escapes too quickly into the bloodstream, you cross a very dangerous line.

You go from localized relief to systemic danger.

And that brings us to the core of pharmacokinetics and managing adverse effects.

Yeah.

The golden rule of pharmacokinetics here is the balance between the rate of absorption and the rates of metabolism.

If your absorption now paces your metabolism, plasma drug levels will rise, and your risk for systemic toxicity just skyrockets.

And just to tie this back to our chemical families,

esters rely on plasma esterases in the blood to be destroyed, amides rely on the liver.

So if you inject a massive dose that absorbs too fast, those specific enzymes get overwhelmed.

The chemical scissors just can't cut fast enough.

And when that happens, the first major bodily system to suffer is the central nervous system.

When absorbed in sufficient amounts, local anesthetics cross the blood -brain barrier and cause a biphasic CNS reaction.

Biphasic meaning it happens in two completely distinct phases.

Correct.

The first phase is excitation.

The drug initially blocks the inhibitory pathways in the brain, leading to hyperactivity.

This excitation can be severe enough to cause convulsions and seizures.

Oh, wow.

Yeah.

And if your patients start seizing, clinical guidelines direct that you manage it immediately with an intravenous benzodiazepine, like diazepam or midazolam, to calm the nervous system.

But you mentioned it's biphasic, so what happens after the brain gets overly excited?

The crash.

The excitation phase is followed by profound CNS depression.

The brain essentially gets exhausted and generalized suppression takes over.

That sounds dangerous.

Very.

This ranges from drowsiness to unconsciousness to coma and even death, secondary to respiratory depression.

The brain literally forgets to tell the lungs to breathe.

If respiratory depression becomes prominent, mechanical ventilation with supplemental oxygen is immediately indicated.

And the toxicity doesn't stop at the brain, right?

The cardiovascular system is highly vulnerable, too, because the heart relies on sodium channels to beat.

Precisely.

These drugs suppress cardiac excitability.

If toxic levels flood the heart, they block those cardiac sodium channels, which can cause bradycardia, severe heart block, reduced contractile force, or even full cardiac arrest.

Unbelievable.

Furthermore, they relax vascular smooth muscles systemically.

So the blood vessels all over the body dilate, causing a massive drop in blood pressure known as severe hypotension.

Okay, let's revisit allergic reactions for a moment because we touched on them earlier.

These can range from a rash or allergic dermatitis to full -blown anaphylaxis, but as you said, this is largely limited to the ester type anesthetics.

Yes.

And here is a crucial clinical pearl for any provider.

There is absolutely no cross allergy between esters and amides.

Really?

None at all?

None.

They are completely different molecular shapes.

If a patient is allergic to an ester, you must assume they are allergic to all other esters, but they are not cross -allergic to amides.

So if your patient has an ester allergy documented in their chart, you can safely switch to an amide like lidocaine.

That is a great tip.

Now, there is one more very specific, very severe adverse effect we have to cover before we talk about specific drugs,

methamoglobinemia.

Yeah.

This is a major safety alert in the field.

Methamoglobinemia is a terrifying blood disorder where the iron in the hemoglobin molecule is chemically altered.

The hemoglobin can still pick up oxygen in the lungs, but it gets locked in a death grip and simply cannot release that oxygen to the tissues.

So the patient is breathing fine, but their tissues are literally suffocating at the cellular level.

Yes.

If enough hemoglobin is converted, it is rapidly fatal.

And this specific reaction is strongly associated with topical benzocaine, which, you know, comes in liquids, sprays, and gels.

And the most tragic part of this warning is the history behind it.

Most of the fatalities and severe cases were in children under the age of two who were simply being treated with over -the -counter benzocaine gel by their parents for common teething pain.

It's awful.

Because of this profound risk, topical benzocaine must not be used in children under two years old, period.

And it should be used with extreme caution, even in adults.

Exactly.

It's a critical safety priority.

Okay.

Hearing all these severe systemic risks, seizures, cardiac arrest, tissue suffocation, I have to push back a little on our bouncer strategy from earlier.

Okay, go ahead.

If rapid absorption into the bloodstream is the main danger, why don't we just use massive, overwhelming amounts of epinephrine every single time?

Like, why not completely clamp down the blood vessels so zero anesthetic escapes?

I mean, it's a logical thought, but you have to respect the power of total vasoconstriction.

If you use massive amounts of epinephrine, you restrict local blood flow so intensely that you cause tissue necrosis.

Oh, jeez.

Yeah.

You are literally starving the local tissue of oxygen until it dies and rots.

Furthermore, if even a fraction of that massive epinephrine dose does slip into the bloodstream, the resulting extreme tachycardia and hypertension could easily trigger a fatal cardiac event, especially in an elderly or compromised patient.

You'd just be trading one - One lethal toxicity for another.

Okay, that makes perfect sense.

Balance is everything in pharmacology.

So now that we understand the rules of pharmacokinetics, the boundaries of toxicity, and the mechanisms of action, let's look at the specific tools you'll actually prescribe.

Let's talk about the prototype drugs.

Great.

We have three main prototypes to review from the chapter.

Let's start with our ester prototype, chloroprocane, which you might see under the brand name Nesicane.

It essentially replaced the original procaine, correct?

Yes.

It's a cleaner evolution.

It is given by injection only.

Because it's an ester, you have to be vigilant about that higher risk for allergic reactions.

But interestingly, systemic toxicity, the seizures and cardiac depression we just discussed, is actually quite rare with chloroprocane.

Wait, why is it less toxic if it works the exact same way?

Because of those plasma ester acids, they deactivate chloroprocane incredibly rapidly in the blood.

Even if it absorbs a bit too fast, the body's chemical scissors chop it up before it can reach the brain or heart in high enough concentrations.

Okay.

Clinically, it's typically administered as a 1 % to 3 % solution injected subcutaneously with a strict maximal adult dose of 800 milligrams.

Next up is our Illumitade prototype, lidocaine, which I imagine almost everyone has heard of.

It is incredibly versatile.

I mean, you can use it topically or by injection.

Lidocaine is the workhorse.

It is faster, more intense, and longer lasting than procaine.

And because it's an MLI, allergic reactions are exceedingly rare, giving it a fantastic safety profile for the general population.

But there is a fascinating secondary use for lidocaine.

Because it suppresses cardiac excitability by blocking those sodium channels, it is actually used in acute care to treat certain cardiac dysrhythmias.

Right.

It is a perfect example of how a drug's mechanism of action can serve dual purposes depending on the route and the indication.

In the skin, it blocks nerve conduction to stop pain.

In the heart, given intravenously, it blocks overactive cardiac sodium channels to stabilize a chaotic heartbeat.

That's wild.

Yeah.

But for local anesthesia, though, it's generally a 0 .5 % to 2 % solution injected subcutaneously with a maximal adult dose of 300 milligrams.

Okay.

And that brings us to the third prototype.

And I have to admit, seeing this in a modern medical curriculum is always a bit jarring.

Cocaine.

Cocaine.

It was actually our very first local anesthetic.

It is an ester -type anesthetic, and despite its reputation, it is still a valid clinical drug.

It is used strictly topically, primarily for anesthesia of the ear, nose, and throat.

How does a clinician justify using a Schedule II controlled substance with such intense cardiovascular and abuse risks?

There must be something it does that lidocaine simply cannot do.

There is.

It comes down to a highly unique pharmacological property.

Cocaine is the only local anesthetic that causes intense, intrinsic vasoconstriction entirely on its own.

Wait.

It has its own built -in bouncer?

How does it do that?

By physically blocking the reuptake of norepinephrine at the sympathetic nerve terminals on blood vessels.

Normally, norepinephrine is released to constrict a vessel and then quickly swept back up.

Cocaine blocks the drain.

Yeah, the norepinephrine stays in the synapse, continuously stimulating the vessels to clamp shut.

This makes it exceptionally useful for procedures involving highly vascular areas, like treating severe unstoppable nosebleeds, where you need profound numbing and profound blood vessel constriction simultaneously.

But because it's already causing intense vasoconstriction, I imagine combining it with epinephrine would be disastrous.

It would be catastrophic.

Like you would induce massive, uncontrolled hypertension and likely a fatal cardiac arrhythmia.

Cocaine should never be combined with epinephrine or any other vasoconstriction.

Never.

Got it.

And because of the profound psychological dependence and systemic cardiovascular risks, its clinical use is strictly limited.

It's usually a 4 % solution applied topically, with a hard maximal dose of 3 mg per kilogram or 160 mg total.

So having met our prototypes, we arrive at the final clinical application.

How you, as an advanced practice nurse or physician assistant, will actually administer these drugs to your patients safely at the bedside.

Broadly, administration falls into two clinical categories.

Topical and injection.

Topical administration is used for skin and nuchus membrane discomfort.

But as we've learned,

just because it's rubbed on the surface doesn't mean it's entirely safe from systemic absorption.

Right.

To minimize that systemic toxicity with topicals, there are very clear rules.

You apply the smallest amount needed, avoid applying it to massive surface areas, and critically avoid applying it to broken or injured skin because the barrier defenses are compromised and the drug will pour directly into the bloodstream.

There is also a vital rule regarding temperature.

You must actively instruct your patients not to wrap the site or apply heating pads to the site.

Because wrapping or heating the numb area is essentially putting a greenhouse over the skin.

It drastically increases the skin temperature and dilates the local blood vessels, which literally bakes the drug straight into the bloodstream.

You completely bypass the safety limits of absorption we rely on.

That's a great visual to keep in mind.

The greenhouse effect.

Now, for injection administration, the stakes are exponentially higher.

The clinical approach differentiates between infiltration, which is injecting directly into the surgical area, like around laceration and nerve blocks, which involve injecting into distant nerves that supply the surgical field.

And nerve blocks require smaller doses, right?

Right.

Because you're targeting the main supply line rather than saturating the whole field.

But whether it's infiltration or a major nerve block, the safety protocols are non -negotiable.

Injections are high -risk events.

They require you to have immediate resuscitation equipment on hand, an active IV line in place to push anti -seizure or cardiac meds if toxicity occurs, and a strict physical technique.

The clinician must aspirate before injecting.

Aspiration is paramount for patient survival.

Before you push the anesthetic into the tissue, you pull back slightly on the plunger of the syringe.

You're looking to see if blood pulls into the barrel.

If it does, it means you have accidentally placed the needle directly inside an artery or vein.

If you push a full localized dose directly into the systemic circulation, you will cause immediate, severe, and potentially fatal toxicity.

So to summarize the key clinical considerations for the provider.

Your therapeutic goal is always reducing localized discomfort without systemic depression.

You must identify high -risk patients, like anyone with a history of ester allergies or kids under two regarding benzocaine.

And once you administer, you must rigorously monitor your patient's vital parameters – blood pressure, pulse, respirations, and their state of consciousness – to catch that biphasic reaction early.

It is all about understanding the physiology beneath the action.

From the microscopic blockade of a single -axanol sodium channel, all the way up to making safe, patient -centered clinical decisions at the bedside.

You are constantly balancing molecular size, blood flow, enzymatic pathways, and specific drug properties to keep the patient safe while keeping them comfortable.

And that concludes our focused deep -dive review of local anesthetics.

A warm thank you to all the students listening from the Last Minute Lecture Team.

It's been a pleasure walking through this with you.

But before we let you get back to your clinical rotations, we want to leave you with one final thing to ponder.

We've talked extensively today about how the liver and plasma esterases are the biological safety nets that clear these drugs from the body.

But what happens when a patient sitting in front of you has an undiagnosed rare genetic variation that drastically slows down those specific plasma esterases?

Could a standard, safe textbook dose of chloroprocane suddenly become a toxic, seizure -inducing overdose before you even realize what's happening?

Keep asking questions, keep studying, and we'll see you next time.